Ensign Peak Advisors Inc Has $3.70 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Ensign Peak Advisors Inc increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,395 shares of the medical equipment provider's stock after purchasing an additional 7,248 shares during the quarter. Ensign Peak Advisors Inc owned 0.06% of Lantheus worth $3,703,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of LNTH. Farallon Capital Management LLC lifted its position in Lantheus by 79.9% during the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after purchasing an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares during the period. Raymond James Financial Inc. bought a new stake in Lantheus during the fourth quarter worth about $36,183,000. Swedbank AB lifted its holdings in shares of Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after acquiring an additional 385,000 shares during the last quarter. Finally, Keybank National Association OH bought a new position in shares of Lantheus in the fourth quarter worth about $27,526,000. Institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of research reports. B. Riley dropped their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Finally, Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $132.67.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This trade represents a 10.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is currently owned by insiders.

Lantheus Price Performance

NASDAQ LNTH traded up $1.46 during trading hours on Friday, reaching $81.24. The company's stock had a trading volume of 913,883 shares, compared to its average volume of 981,515. The firm has a fifty day simple moving average of $97.11 and a 200-day simple moving average of $93.20. The stock has a market cap of $5.62 billion, a P/E ratio of 13.52 and a beta of 0.23. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm's quarterly revenue was up .8% compared to the same quarter last year. During the same quarter last year, the business earned $1.69 EPS. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.